Form 8-K - Current report:
SEC Accession No. 0001193125-23-255616
Filing Date
2023-10-13
Accepted
2023-10-13 06:40:00
Documents
16
Period of Report
2023-10-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d558552d8k.htm   iXBRL 8-K 29075
2 EX-99.1 d558552dex991.htm EX-99.1 43755
6 GRAPHIC g558552dsp11_capture.jpg GRAPHIC 9647
7 GRAPHIC g558552g1012073601632.jpg GRAPHIC 3231
8 GRAPHIC g558552g1012073609882.jpg GRAPHIC 1116
  Complete submission text file 0001193125-23-255616.txt   226440

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nuvl-20231013.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nuvl-20231013_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nuvl-20231013_pre.xml EX-101.PRE 11710
10 EXTRACTED XBRL INSTANCE DOCUMENT d558552d8k_htm.xml XML 3469
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40671 | Film No.: 231323821
SIC: 2834 Pharmaceutical Preparations